HRP20200600T1 - Tapentadol za sprječavanje i liječenje depresije i tjeskobe - Google Patents
Tapentadol za sprječavanje i liječenje depresije i tjeskobe Download PDFInfo
- Publication number
- HRP20200600T1 HRP20200600T1 HRP20200600TT HRP20200600T HRP20200600T1 HR P20200600 T1 HRP20200600 T1 HR P20200600T1 HR P20200600T T HRP20200600T T HR P20200600TT HR P20200600 T HRP20200600 T HR P20200600T HR P20200600 T1 HRP20200600 T1 HR P20200600T1
- Authority
- HR
- Croatia
- Prior art keywords
- tapentadol
- use according
- anxiety
- administered
- preventing
- Prior art date
Links
- KWTWDQCKEHXFFR-SMDDNHRTSA-N tapentadol Chemical compound CN(C)C[C@H](C)[C@@H](CC)C1=CC=CC(O)=C1 KWTWDQCKEHXFFR-SMDDNHRTSA-N 0.000 title claims 12
- 229960005126 tapentadol Drugs 0.000 title claims 12
- 208000019901 Anxiety disease Diseases 0.000 title claims 2
- 230000036506 anxiety Effects 0.000 title claims 2
- 229940098747 AMPA receptor antagonist Drugs 0.000 claims 1
- 239000000775 AMPA receptor antagonist Substances 0.000 claims 1
- 208000020401 Depressive disease Diseases 0.000 claims 1
- 239000001961 anticonvulsive agent Substances 0.000 claims 1
- 229960003965 antiepileptics Drugs 0.000 claims 1
- 230000002917 arthritic effect Effects 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 239000002831 pharmacologic agent Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (6)
1. Tapentadol naznačen time da je za upotrebu za liječenje depresije i/ili tjeskobe kod subjekta koji pati od kronične artritične boli, pod uvjetom da se tapentadol ne primjenjuje u kombinaciji s antiepileptikom.
2. Tapentadol za uporabu prema zahtjevu 1, pod uvjetom da se tapentadol ne primjenjuje u kombinaciji s antagonistom AMPA receptora.
3. Tapentadol za uporabu prema zahtjevu 1 ili 2, naznačen time da se tapentadol primjenjuje kao jedini farmakološki aktivni sastojak.
4. Tapentadol za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time da se tapentadol primjenjuje oralno.
5. Tapentadol za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time da se tapentadol primjenjuje
- jednom dnevno ili dva puta dnevno, i/ili
- u dnevnoj dozi u rasponu od 25 do 600 mg.
6. Tapentadol za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time da je bol umjerena ili teška.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11003508 | 2011-04-29 | ||
| EP17185830.1A EP3272343B1 (en) | 2011-04-29 | 2012-04-27 | Tapentadol for preventing and treating depression and anxiety |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20200600T1 true HRP20200600T1 (hr) | 2020-10-16 |
Family
ID=44260882
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171570TT HRP20171570T1 (hr) | 2011-04-29 | 2017-10-16 | Tapentadol za sprječavanje i liječenje depresije i tjeskobe |
| HRP20200600TT HRP20200600T1 (hr) | 2011-04-29 | 2020-04-15 | Tapentadol za sprječavanje i liječenje depresije i tjeskobe |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171570TT HRP20171570T1 (hr) | 2011-04-29 | 2017-10-16 | Tapentadol za sprječavanje i liječenje depresije i tjeskobe |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20120277319A1 (hr) |
| EP (3) | EP3272343B1 (hr) |
| JP (3) | JP6014655B2 (hr) |
| CY (2) | CY1119586T1 (hr) |
| DK (2) | DK3272343T3 (hr) |
| ES (2) | ES2788548T3 (hr) |
| HR (2) | HRP20171570T1 (hr) |
| HU (2) | HUE049308T2 (hr) |
| LT (2) | LT3272343T (hr) |
| NO (1) | NO2701693T3 (hr) |
| PL (2) | PL3272343T3 (hr) |
| PT (2) | PT3272343T (hr) |
| RS (2) | RS60152B1 (hr) |
| SI (2) | SI3272343T1 (hr) |
| WO (1) | WO2012146383A1 (hr) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
| DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
| DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| RU2567723C2 (ru) | 2009-07-22 | 2015-11-10 | Грюненталь Гмбх | Стабильная при окислении, прочная на излом лекарственная форма |
| CA2839123A1 (en) | 2011-07-29 | 2013-02-07 | Grunenthal Gmbh | Tamper-resistant tablet providing immediate drug release |
| DK2736497T3 (da) | 2011-07-29 | 2017-11-13 | Gruenenthal Gmbh | Stød-resistent tablet, der tilvejebringer en øjeblikkelig frigivelse af et lægemiddel. |
| US10813630B2 (en) | 2011-08-09 | 2020-10-27 | Corquest Medical, Inc. | Closure system for atrial wall |
| US10307167B2 (en) | 2012-12-14 | 2019-06-04 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
| US10314594B2 (en) | 2012-12-14 | 2019-06-11 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
| US20140142689A1 (en) | 2012-11-21 | 2014-05-22 | Didier De Canniere | Device and method of treating heart valve malfunction |
| AU2014289187B2 (en) | 2013-07-12 | 2019-07-11 | Grunenthal Gmbh | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
| EP2845625A1 (en) * | 2013-09-04 | 2015-03-11 | Grünenthal GmbH | Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome |
| MX371372B (es) | 2013-11-26 | 2020-01-28 | Gruenenthal Gmbh | Preparacion de una composicion farmaceutica en polvo por medio de criomolienda. |
| US9566443B2 (en) | 2013-11-26 | 2017-02-14 | Corquest Medical, Inc. | System for treating heart valve malfunction including mitral regurgitation |
| US10842626B2 (en) | 2014-12-09 | 2020-11-24 | Didier De Canniere | Intracardiac device to correct mitral regurgitation |
| CN107660147B (zh) * | 2015-05-26 | 2021-04-30 | 抗菌技术生物技术研究与发展股份有限公司 | 用于治疗帕金森病和相关障碍的组合物 |
| CA2998259A1 (en) | 2015-09-10 | 2017-03-16 | Grunenthal Gmbh | Protecting oral overdose with abuse deterrent immediate release formulations |
| US10292948B2 (en) * | 2017-01-11 | 2019-05-21 | Torrent Pharmaceuticals Limited | Tapentadol nasal composition |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4783337A (en) | 1983-05-11 | 1988-11-08 | Alza Corporation | Osmotic system comprising plurality of members for dispensing drug |
| US4612008A (en) | 1983-05-11 | 1986-09-16 | Alza Corporation | Osmotic device with dual thermodynamic activity |
| US4765989A (en) | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
| DE4426245A1 (de) | 1994-07-23 | 1996-02-22 | Gruenenthal Gmbh | 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung |
| PE20030527A1 (es) | 2001-10-24 | 2003-07-26 | Gruenenthal Chemie | Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen |
| JP2009506076A (ja) | 2005-08-26 | 2009-02-12 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・レランド・スタンフォード・ジュニア・ユニバーシティ | 三叉神経疼痛のための薬物送達のための治療手順 |
| WO2007088473A2 (en) | 2006-02-03 | 2007-08-09 | Neurocure Ltd | Treatment and prevention of depression with pain, depression secondary to pain, and of neuropathic pain |
| EP2012763B1 (en) | 2006-04-28 | 2011-03-23 | Grünenthal GmbH | Pharmaceutical combination comprising 3- (3-dimethylamin0-1-ethyl-2-methyl-pr0pyl) -phenol and an nsaid |
| DE102007012165A1 (de) | 2007-03-12 | 2008-09-18 | Grünenthal GmbH | Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie des Neuropathieschmerzes |
| EP1985292A1 (en) | 2007-04-23 | 2008-10-29 | Grünenthal GmbH | Titration of tapentadol |
| MX2010005680A (es) | 2007-11-23 | 2010-12-21 | Protect Pharmaceutical Corp | Composiciones de tapentadol. |
| US20100297181A1 (en) | 2007-12-26 | 2010-11-25 | Eisai R&D Management Co., Ltd. | AMPA Receptor Antagonists for Epilepsy, Mental Disorders or Deficits in Sensory Organ |
| US7868043B2 (en) | 2008-01-25 | 2011-01-11 | Xenoport, Inc. | Mesophasic forms of (3S)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use |
| US7872046B2 (en) | 2008-01-25 | 2011-01-18 | Xenoport, Inc. | Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use |
| US20100227921A1 (en) | 2009-03-03 | 2010-09-09 | Shire Llc | Amino acid and peptide carbamate prodrugs of tapentadol and uses thereof |
| EP3069717A1 (en) | 2009-04-30 | 2016-09-21 | Grünenthal GmbH | Use of 1-phenyl-3-dimethylaminopropane compounds for treating rheumatoid pain |
| FR2970261B1 (fr) | 2011-01-10 | 2013-05-03 | IFP Energies Nouvelles | Procede d'hydrotraitement de charges lourdes d'hydrocarbures avec des reacteurs permutables incluant au moins une etape de permutation progressive |
| EP2694049B1 (en) | 2011-04-05 | 2018-10-31 | Grünenthal GmbH | Tapentadol for preventing chronification of pain |
-
2012
- 2012-04-27 JP JP2014506793A patent/JP6014655B2/ja active Active
- 2012-04-27 PT PT171858301T patent/PT3272343T/pt unknown
- 2012-04-27 PT PT127207942T patent/PT2701693T/pt unknown
- 2012-04-27 SI SI201231768T patent/SI3272343T1/sl unknown
- 2012-04-27 NO NO12720794A patent/NO2701693T3/no unknown
- 2012-04-27 EP EP17185830.1A patent/EP3272343B1/en active Active
- 2012-04-27 US US13/458,510 patent/US20120277319A1/en not_active Abandoned
- 2012-04-27 SI SI201231099T patent/SI2701693T1/sl unknown
- 2012-04-27 ES ES17185830T patent/ES2788548T3/es active Active
- 2012-04-27 PL PL17185830T patent/PL3272343T3/pl unknown
- 2012-04-27 RS RS20200431A patent/RS60152B1/sr unknown
- 2012-04-27 ES ES12720794.2T patent/ES2646363T3/es active Active
- 2012-04-27 DK DK17185830.1T patent/DK3272343T3/da active
- 2012-04-27 RS RS20171076A patent/RS56523B1/sr unknown
- 2012-04-27 EP EP12720794.2A patent/EP2701693B1/en active Active
- 2012-04-27 EP EP19218383.8A patent/EP3656380A1/en not_active Withdrawn
- 2012-04-27 HU HUE17185830A patent/HUE049308T2/hu unknown
- 2012-04-27 WO PCT/EP2012/001819 patent/WO2012146383A1/en active Application Filing
- 2012-04-27 LT LTEP17185830.1T patent/LT3272343T/lt unknown
- 2012-04-27 LT LTEP12720794.2T patent/LT2701693T/lt unknown
- 2012-04-27 PL PL12720794T patent/PL2701693T3/pl unknown
- 2012-04-27 DK DK12720794.2T patent/DK2701693T3/da active
- 2012-04-27 HU HUE12720794A patent/HUE034003T2/en unknown
-
2014
- 2014-09-30 US US14/502,552 patent/US20150018426A1/en not_active Abandoned
-
2016
- 2016-09-20 JP JP2016183088A patent/JP2017031182A/ja active Pending
-
2017
- 2017-03-27 US US15/470,385 patent/US9980927B2/en active Active
- 2017-08-29 JP JP2017163838A patent/JP6445637B2/ja active Active
- 2017-10-16 HR HRP20171570TT patent/HRP20171570T1/hr unknown
- 2017-11-10 CY CY20171101178T patent/CY1119586T1/el unknown
-
2020
- 2020-04-15 HR HRP20200600TT patent/HRP20200600T1/hr unknown
- 2020-04-16 CY CY20201100360T patent/CY1123051T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200600T1 (hr) | Tapentadol za sprječavanje i liječenje depresije i tjeskobe | |
| JP2013505282A5 (hr) | ||
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| WO2014205229A8 (en) | Use of high dose pridopidine for treating huntington's disease | |
| JP2015515475A5 (hr) | ||
| JP2015523407A5 (hr) | ||
| JP2012193216A5 (hr) | ||
| JP2015057451A5 (hr) | ||
| JP2010222367A5 (hr) | ||
| BR112013016862A2 (pt) | combinação de um agonista de opioide e um antagonista de opioide no tratamento de doença de parkinson | |
| NZ605469A (en) | Nalbuphine-based formulations and uses thereof | |
| MA37455A1 (fr) | Utilisation d'un dérivé de pyrazole dans le traitement d'exacerbations aigues d'une maladie pulmonaire obstructive chronique | |
| WO2011159100A3 (ko) | 항암 활성을 나타내는 약제학적 조성물 | |
| JP2013516493A5 (hr) | ||
| EA201400737A1 (ru) | Система доставки на основе множества пеллет с немедленным высвобождением активного вещества | |
| BR112013010829B8 (pt) | Composição farmacêutica intravenosa para proporcionar alívio da dor e/ou da inflamação | |
| JP2016527312A5 (ja) | ヒスタミンｈ４受容体を介してもたらされた掻痒状態を治療するための医薬組成物 | |
| JP2013541583A5 (hr) | ||
| WO2007145863A3 (en) | Sustained release formulation of naltrexone | |
| MX2016007682A (es) | Composicion farmaceutica que comprende ivabradina amorfa. | |
| JP2012502915A5 (hr) | ||
| WO2012085249A3 (en) | Homogenous pharmaceutical oral dosage forms comprising lercanidipine and enalapril or their pharmaceutically acceptable salts together with an organic acid | |
| JP2015516452A5 (hr) | ||
| MX2010013484A (es) | Formulaciones en dosis unitaria de ketorolaco para administración intra-nasal. | |
| MX2013008992A (es) | Composicion farmaceutica con agentes antiinflamatorios y proceso de produccion. |